University of Connecticut

OpenCommons@UConn
Master's Theses

University of Connecticut Graduate School

8-7-2018

Examining the Role of Histidine in the
Antimicrobial Peptide Gaduscidin-1
Jasmin Portelinha
jasmin.portelinha@uconn.edu

Recommended Citation
Portelinha, Jasmin, "Examining the Role of Histidine in the Antimicrobial Peptide Gaduscidin-1" (2018). Master's Theses. 1284.
https://opencommons.uconn.edu/gs_theses/1284

This work is brought to you for free and open access by the University of Connecticut Graduate School at OpenCommons@UConn. It has been
accepted for inclusion in Master's Theses by an authorized administrator of OpenCommons@UConn. For more information, please contact
opencommons@uconn.edu.

Portelinha

Examining the Role of Histidine in the Antimicrobial Peptide Gaduscidin-1

Jasmin Portelinha
B.S. Chemistry, University of New Haven, 2016
B.S. Biology, University of New Haven, 2016

A Thesis
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Master of Science
At the
University of Connecticut
2018

Portelinha ii
Copyright by
Jasmin Portelinha

2018

Portelinha iii

APPROVAL PAGE
Masters of Science Thesis

Examining the Role of Histidine in the Antimicrobial Peptide Gaduscidin-1

Presented by
Jasmin Portelinha, B.S.

Major Advisor
Dr. Alfredo M. Angeles-Boza

Associate Advisor
Dr. Mark Peczuh

Associate Advisor
Dr. Challa Kumar

Associate Advisor
Dr. Alex Gorka

University of Connecticut
2018

Portelinha iv

Table of Contents
Chapter 1. Introduction to antibiotic resistance and antimicrobial peptides ........................................ 3
1.1 Mechanisms of antibiotic resistance .......................................................................................... 4
1.2 AMPs as a solution to ABX Resistance ..................................................................................... 9
1.3 Mode of action of AMPs ......................................................................................................... 11
1.4 Piscidins and gaduscidin-1 as therapeutic AMPs ................................................................... 17
Chapter 2. Investigating gad-1 for metal ion binding and antimicrobial applications....................... 29
2.1 Introduction .............................................................................................................................. 30
2.2 Metal ion binding ..................................................................................................................... 31
2.3 Secondary structure determination........................................................................................... 35
2.4 Antimicrobial activity .............................................................................................................. 39
2.5 Mechanism of action ................................................................................................................ 41
2.6 Toxicity .................................................................................................................................... 43
2.7 Discussion ................................................................................................................................ 44
2.8 Conclusion ............................................................................................................................... 46
Chapter 3. Experimental methods........................................................................................................... 48
3.1 Cu titration ............................................................................................................................... 49
3.2 Zincon titration......................................................................................................................... 49
3.3 Electrospray ionization mass spectrometry (ESI-MS) ............................................................. 49
3.4 CD measurements .................................................................................................................... 50
3.5 MIC and MBC measurements ................................................................................................. 50
3.6 Time kill kinetics (TKK) measurements .................................................................................. 51
3.7 β-galactosidase leakage assay .................................................................................................. 51
3.8 Lipid peroxidation assay .......................................................................................................... 52
3.9 Hemolysis ................................................................................................................................ 52

Portelinha v
Abstract
Antimicrobial peptides (AMPs) have broad spectrum antimicrobial activity and are predominately
short (11-100 amino acid), amphipathic, α-helical, and cationic peptides. AMPs are ubiquitous in nature
but only a small number of natural AMPs have metal binding motifs involving the amino acid histidine.
Examples are the Amino Terminal Copper and Nickel Binding Unit (ATCUN) and the HXXXH motif.
The ATCUN motif is found in many natural AMPs and consists of an XXH motif at the N-terminus,
while the HXXXH motif, coordinates Zn2+ ions when in an α-helical formation because the two histidines
are positioned on the same face of the helix. Gaduscidin 1 (gad-1) is an AMP derived from Atlantic cod
fish. Gad-1 is an α-helical peptide with 21 amino acids, five of which are histidine residues, and contains
an ATCUN motif and an HXXXH motif. Herein, we investigate the role of histidine and metal binding in
the antimicrobial activity of gad-1. We will present our current understanding of the mechanisms by
which gad-1 induces bacterial cell death. Our data indicates that gad-1 targets the membrane based on βgalactosidase and lipid peroxidation experiments. The activity of gad-1 is potentiated by the ATCUN
motif, as the absence of the histidine in the third position lowers the activity against Escherichia coli
eight-fold. The role of the HXXXH motif is unclear in gad-1, however despite the loss of the ATCUN
motif, the peptide still retains some activity that could be potentiated by the HXXXH motif. The HXXXH
motif is likely used as a second Cu2+ binding site, as gad-1 was shown to bind two Cu2+ ions using mass
spectrometry. Based on lipid peroxidation experiments it is possible that this binding site, along with the
ATCUN binding site, can produce ROS and peroxidize lipids giving gad-1 a multi-hit mode of action.
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CHAPTER 1
Introduction to antibiotic resistance and antimicrobial peptides
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1.1 Mechanisms of antibiotic resistance
In the United States, more than 23,000 people will die annually as a result of drug-resistant
bacterial infections.1 The increase in drug-resistant pathogens is attributed to usage of antibiotics (ABXs)
in the agricultural and livestock industry coupled with nosocomial infections, inadequate diagnoses,
pressure by doctors to prescribe ABXs for viruses, and unfinished ABX doses by patients. Over 50% of
prescribed ABXs are not necessary nor optimal treatments, leading to the need for more ABXs to be
used.1 Many drug companies want to develop more profitable drugs than ABXs, which may be why the
number of new ABXs have waned since the 1980’s, decreasing by more than 75% from 1980-1984
compared to 2010-2014.2 New treatment alternatives are desperately needed as the number of new cases
of ABX resistant superbugs increase annually.2 Options such as antimicrobial peptides (AMPs) can be
used as novel antimicrobial agents against drug-resistant pathogens.
The rise in resistance has been correlated with increased ABX usage.3 From 2000 to 2015 there
was a 39% increase in ABX consumption worldwide that caused an escalation in the number of resistant
pathogens.3 In 2011, there were a total of 2,049,442 drug-resistant cases reported with the main problems
being methicillin resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, nontyphoidal
Salmonella spp., Neisseria gonorrhoeae, and Campylobacter spp.1 Other troubling pathogens were
defined by The World Health Organization (WHO) as the ESKAPE pathogens, which are comprised of
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa, and Enterobacter spp.4 The concern surrounding these ESKAPE species are
that they commonly cause nosocomial infections and are acquired mainly by patients whose immune
systems are already compromised.4 As an example of how quickly resistance can spread, the mcr-1
plasmid, which yields resistance to colistin (polymyxin E), a last line ABX, was discovered in
Escherichia coli in China5 and another E. coli strain in the US was found shortly after with the same
plasmid.6 The E.coli isolate had a total of 15 ABX resistance genes and was either resistant or susceptible
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to the most frequently used ABXs.6 ABX resistance is a major concern and is becoming a worldwide
issue that needs to be addressed with more research into new ABX alternatives.
Novel compounds with pathogen targets that do not easily mutate or confer resistance are greatly
needed. The three main targets of traditional ABXs are inhibition of cell wall synthesis, nucleic acid
synthesis, and protein synthesis. Due to the specific targets of ABXs, a pathogen can acquire a multitude
of strategies to develop resistance to specific ABXs or can potentially gain multi-drug resistance (MDR)
mechanisms. A pathogen can mutate an allosteric or active site to inhibit binding of an ABX, can acquire
plasmids with multiple resistance genes, have mobile transposable chromosomal elements, or can produce
inhibitory enzymes to confer resistance (Figure 1). Efflux pumps, which push ABXs out of the cell, can
be specific for one type of ABX or can export multiple ABX classes and contribute to MDR.7 Plasmids
are easily acquirable from other bacteria via horizontal gene transfer, causing rapid spread of resistance in
a population.8,9 Pathogens can also acquire broad spectrum resistance by altering their cell wall
composition, although this may require too much energy to be advantageous for the cell.8,10

Antibiotic Resistance Acquisition Methods

Figure 1. Summary of methods that lead to ABX resistance
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One example of an ABX class that inhibits cell wall synthesis are β-lactams. 9,11 This class targets
the peptidoglycan cell wall synthesis in Gram-positive [G(+)] bacteria and to some extent in Gramnegative [G(-)] bacteria by binding to the crosslinkers, [i.e. penicillin-binding proteins (PBPs)], that form
a thick polymeric layer of sugar and amino acids (AAs) during peptidoglycan synthesis. 9,11 By binding
the crosslinkers, β-lactams halt cell growth and weaken the cellular membrane. 9,11 Various examples of
resistance have been demonstrated against β-lactams. One major mechanism driving resistance is the
production of β-lactamases, enzymes that break down β-lactam ABXs.9 In G(-) bacteria, the β-lactamases
can widen their active site to confer better activity against cephalosporin, a member of the β-lactams, but
this alteration comes at the cost of also allowing other ABXs to be more active.9 A family of β-lactamases
derived from natural cephalosporinases have proven to be a large problem with resistance in many
pathogenic species but specifically with K. pneumoniae a member of the ESKAPE pathogens.9
Carbapenems are one of last line ABXs for G(-) bacteria, because they are resistant to hydrolysis by most
β-lactamases.9 Therefore, the acquisition of plasmids that produce carbapenemases, have compromised
this last line ABX.9 The production of low affinity PBPs is another concerning mechanism of resistance.9
A mobile chromosome named mec encodes PBP2a, a protein which contains a low affinity β-lactam
binding site that is found in MRSA species and confers resistance to most known β-lactams without
hindering the normal cell wall synthesis processes of the bacteria.9 The PBP genes can be recombined, as
is the case with Streptococcus spp. that have acquired resistance through mosaic genes.9
Another class of ABX used as a last line of defense for G(-) infections are polymyxins, which are
peptides that disrupt the cell membrane.10 Polymyxin B and colistin (polymyxin E) are cyclic, cationic
peptides with fatty acid tails.12 Polymyxin B specifically binds to lipid A of lipopolysaccharide (LPS), a
component of the cell membrane of G(-) bacteria, through electrostatic interactions and disrupts the
membrane to cause cell death.10 The major resistance mechanism against polymyxins is the change in
composition of LPS, more specifically the lipid A component of LPS.10 PmrAB-regulated genes can
produce enzymes that add 4-aminoarabinose to the 4'-phosphate group on lipid A that decreases the net
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charge of the LPS from -1.5 to 0.10 When there are missense mutations in either the A or B components,
the resulting pmrC will be upregulated to alter lipid A by adding 4-aminoarabinose or
phosphoethanolamine (PEtN).10 The addition of a PEtN moiety to the 1' and 4' phosphate groups will
reduce the charge from -1.5 to -1.10 By making these charge modifications, the initial electrostatic
interactions that allows the peptide ABX to bind to the LPS become limited and thereby reducing the
efficacy of polymyxins.
Although cell wall inhibitors are common, several classes of ABXs target intracellular
components such as DNA and proteins. DNA gyrase and topoisomerase IV are both involved in strand
breaks when DNA is replicating, the process of supercoiling DNA, and inhibiting DNA synthesis.13,24
Quinolones or fluoroquinolones target these enzymes in G(-) and G(+) bacteria and include the ABXs
ciprofloxacin, nalidixic acid, norfloxcacin, and ofloaxin.13 Quinolones work when two drug molecules
intercalate into the cleaved or replicating DNA strand by binding to DNA gyrase and the DNA forming
an ABX-enzyme-DNA complex to prevent DNA ligation.13 Permanent chromosomal breaks result and
lead to an SOS response due to the DNA synthesis inhibition via the accumulation of reactive oxygen
species (ROS) that can help mediate cell death.13,14 Resistance can occur when one or both of the
enzymes are mutated, which has been demonstrated by multiple point mutations in gyrA and parC.9,13 An
equally important mechanism of resistance is plasmid mediated, including Qnr proteins and [aac(6')-Ib-cr]
that can decrease the binding events of DNA gyrase and DNA topoisomerase IV.9,13,14 This limits the
number of cleavage sites the quinolones can intercalate into to provide protection from the ABX.9,13,14 In
addition to this, increasing expression and acquisition of multiple efflux pumps can lead to resistance by
pumping the quinolones out of the cell.9,13
Two other ABXs that affect DNA synthesis and are threatened by drug-resistance are
trimethaprim and sulfonamides, which both target folic acid metabolism.24 Sulfonamides specifically
target and competitively inhibit the enzyme dihydropteroate synthase, which is involved in one of the last
steps in the synthesis of folic acid.15 Sulfonamides are active against G(-) and G(+) organisms and are
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selective because mammalian cells do not produce dihydropteroate synthase.15 ABX resistance to
sulfonamides has been rapid due to the alteration of the enzyme active site by changing AAs in the
sequence or by adding more AAs to change the tertiary structure.15 Resistance mediated gene transfer
between species of the same bacteria, such as Neisseria meningiditis and N. gonorrheae, has also led to
the rapid increase in resistance against sulfonamides.15 Trimethoprim is also a competitive inhibitor, but
of dihydrofolate reductase in bacteria, and inhibits folic acid synthesis at a later point than sulfonamides,
meaning that both drugs can be used synergystically.15 The most common cause of trimethoprim
resistance is plasmid acquisition from other resistant bacteria.15
The last of the three main targets that ABXs use to inhibit bacteria is inhibition of protein
synthesis. Aminoglycosides target and bind the 30S ribosome, specifically bacterial ribosomes, as
mammalian ribosomes are structurally different. 8,11 They target the aminoacyl (A-site) of the ribosomes,
which is where the t-RNA binds first during protein synthesis.8 An rRNA methyltransferase, that can be
plasmid acquired, can be expressed to methylate the A-site on the 16s rRNA inhibiting aminoglycosides
binding.8 Mutations in the rrs gene and production of aminoglycosidase-modifying enzymes can lead to
the inability of aminoglycosides to bind to 16s rRNA or mutate specific sites that inhibit binding.8
Furthermore, multi-drug efflux pumps can be overexpressed to inhibit aminoglycoside efficiency, while
porins can narrow, be downregulated, or stop being expressed, as they may be potentially responsible for
transport into the cell.8 Similar to polymyxin, LPS modifications could confer resistance to G(-) bacteria
because aminoglycosides are cationic.8
In short, the mechanisms of ABX resistance includes plasmid acquisition, with multiple drug
resistance cassettes, increasing expression of efflux pumps, enzyme production to degrade the ABX, gene
mutations, and modification of active sites to inhibit ABX binding. Pathogens have figured out how to
dodge modern ABX and proliferate with minimum effort or effect on their normal cellular processes, with
some pathogens being resistant to all known ABX available in the US.16 It is urgent that more research is
done to identify new classes of ABX compounds that pathogens do not develop resistance to quickly.
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1.2 AMPs as a solution to ABX resistance
AMPs are potential lead candidates as novel antimicrobial agents due to their broad spectrum
activity as they have been reported to be inhibitory towards bacteria17–21 , fungi22,23, viruses24, parasites25–
28

, and cancer29,30. The development of AMPs as therapeutics has been investigated for decades.31 AMPs

could represent a unique drug class to fight drug-resistant pathogens, as they can be used alone as a last
line of defense or in synergy with existing ABX to lower the dosages needed to kill pathogens.32,33 One
reason that AMPs are sought-after as therapeutics is that this class targets the cell membrane of
pathogens, which is something that is unlikely to stimulate resistance.8 The mechanism is non-specific,
and the amount of energy needed for a cell to change their entire cell wall composition would likely kill
the cell.8 AMPs are short (11-100 AAs), usually cationic with a few anionic exceptions34, amphipathic
peptides that are found ubiquitously in nature and are important to the innate immunity of a multitude of
animals, insects, and plants.35 AMPs are mainly α-helical17,20,36 but can adopt β-sheet18,37, loop38,39,
cyclic37,40, and disordered structures.41 Most AMPs selectively target bacteria based on cell wall
composition.42 The composition of the lipid bilayer in bacteria is comprised of mostly negatively charged
lipids, mainly phosphatidylethanolamine (PE) and phosphatidylglycerol (PG) with some cardiolipin and
phosphatidylserine (PS).43 Mammalian cells are zwitterionic and, unlike bacteria, are made up of mostly
neutral lipids with negatively charged lipids residing on the opposite face of the bilayer.44 Mammalian
cell membranes are composed of ~25% cholesterol and ~10% sphingomyelin that induce an overall more
rigid bilayer that increases order and inhibits interaction of AMPs that could lead to specificity for
bacterial cells.42,44,45 G(-) bacteria have an outer and inner membrane with the outer membrane being
covered in LPS.43 In G(-) bacteria, the initial attraction of the AMP to the bacterial cell is electrostatic
between the cationic peptide and the LPS where the AMPs displace Ca2+ and Mg2+ on the LPS and
subsequently bind, causing outer membrane disruption and uptake of the AMPs.12 The cytoplasmic
membrane is then targeted where translocation or membrane disruption occurs.12 Conversely, G(+)
bacteria do not have an outer membrane but do have negatively charged components on their cell wall
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called lipoteichoic acid and wall teichoic acid.43 These negatively charged components make up 60% of
the cell wall mass, while the rest of their cell wall is composed of a thick wall of peptidoglycan.43
Expanding upon the various advantages of AMPs as therapeutic options, including selectivity for
bacterial cells, there are metal binding motifs that utilize metal ions abundant in the body such as Cu2+
and Zn2+ to potentiate greater activity. For example, the amino-terminal Cu2+ and Ni2+ (ATCUN) binding
motif and the HXXXH motif bind Cu2+ and Zn2+,
respectively.36,46 Both of these motifs include histidine,
which is important for metal binding and is intriguing
because of its pH dependent activity. The pKa of
histidine is 6; therefore, at pH lower than 6 the histidine
will carry a +1 charge that confers higher activity likely
due to the increased charge of the peptide. The ATCUN
motif is naturally found in albumin, histatin, and
protamine P2a.46 The ATCUN motif is located at the Nterminus of a peptide and is composed of H2N-XXH,
where the XX component of the motif can be any amino
acid except for proline.46 Cu2+ is bound in a square planar
geometry to the free N-terminus, the backbone of the two
deprotonated Namide, and the imidazole ring of histidine
(Figure 2).46 The ATCUN motif has been postulated to
induce higher activity due to the production of ROS that
are produced through redox cycling of Cu2+ to Cu3+ at the
membrane interface (Figure 2).47 ROS can oxidize lipids
or if the peptide is intracellular, can oxidatively nick and

Figure 2. (A) ATCUN sequence without and B) with
Cu2+ bound (C) Fenton-type Cu2+ to Cu3+ redox cycling

cleave DNA and in some cases become linearized
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leading to cell death.47 Multiple examples exist where the ATCUN motif produces ROS that target the
membrane and oxidizes lipids in the bilayer.48,49 The addition of the ATCUN motif to several AMPs has
been investigated and an increase in activity was reported showing that this metal binding motif can
potentiate activity by utilizing two mechanisms: (1) pore formation and (2) lipid peroxidation.50,51 One
example showed that when WRWYCR, an intracellular peptide known to enter cells and bind to Holliday
Junctions, is conjugated to an ATCUN motif, the peptide is able to produce ROS and cleave DNA and
RNA but only when the ATCUN motif is present.52 The HXXXH motif has recently been examined for
Zn2+ binding.36 Previously, the AMP clavanin A, isolated from Steyla clava, has shown a 16-fold increase
in activity against E. coli when Zn2+ is present.36 It was elucidated through the use of alanine mutants that
the HXXXH motif is responsible for the Zn2+ binding and potentiating activity.36
1.3 Mode of action of AMPs
There are several mechanisms for AMPs to target and kill pathogens. Membrane lytic activity has
been noted for almost all AMPs that have been presently isolated with exceptions that will be discussed
later. Disruption of the membrane is the major mechanism of this class of molecules with clear and wellstudied examples including magainin 2 and melittin.17,53 The amphipathic nature of α-helices and β-sheets
allow membrane interactions with the polar lipid heads and fatty acid tails that causes membrane
disruption seen in AMPs but is not required for membrane activity.42 In order to have membrane
disrupting activity against pathogens, the density of AMPs needs to reach a certain threshold to cause
lysis of cells, commonly in the µM range.29 When the peptide:lipid ratio needed for disruption is >1:100
but < 1:1000, the peptide can be characterized as an AMP, while if the ratio is >1:1000, it is considered a
peptide toxin as is the case with melittin and alamethicin.42 AMPs prefer to target at curvatures or at the
septa of multiplying cells and do so faster than with nonseptated cells, causing cell shrinkage in both G(-)
and G(+) bacteria.54,55 The AMPs generally attack at a curvature where new cell membrane is being
synthesized, specifically at the septa in a dividing cell or at a pole of a single cell.54 This may be due to
several reasons such as the lower lipid to peptide ratio at the newly synthesizing bilayer or the shape of
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the lipid at the curve.54. Once the peptide makes a hole, the pore causes rapid depolarization of the cell
membrane and leakage of cellular contents that causes cell death.56 The peptides accumulate on the
surface of the membrane and then organize themselves to form pores.35 Multiple mechanisms describing
how membrane disruption occurs have been proposed, including the carpet model, toroidal pore model,
and the barrel stave model (Figure 3). The carpet model suggests that the AMPs lay parallel to the bilayer
to create a “carpet” where pores are formed, and the bilayer collapses onto itself and destroys the
membrane.57 The toroidal pore model proposes that the curvature of the membrane is affected when the
peptide integrates perpendicular to the membrane and induces curvature while disrupting the membrane
separation of the lipid tails and polar head groups of the lipids.42 The barrel stave model describes how
peptides interact with each other to form ion channels in the bilayer by aligning perpendicular to the
membrane and forming water-filled pores that traverse the membrane.42,57 The toroidal pore and barrel
stave models are similar and both implicate that cell death occurs when the cellular contents leak out of
the cell.57
One of the most studied AMPs to date is magainin 2 (GIGKFLHSAKKFGKAFVGEIMNS), a
membrane active peptide.17 It was originally isolated in 1987 from the epidermis of the frog Xenopus
laevis.17 It is an α-helical peptide that is potent towards G(+) and G(-) bacteria, as well as fungi.17
Magainin 2 selectively targets bacteria, as it does not lyse human erythrocytes.58 When sterols were
present in model membranes, the lytic ability was drastically reduced, again indicating selectivity for
bacterial lipid composition and cell wall components.58 The major mode of action is disruption by the
formation of pores in the bacterial cell membrane and lysis of the inner membrane of G(-) bacteria if the
lipids were acidic.59,60 It has been postulated that pores are formed from the α-helical peptide that spans
the bilayer to aggregate and make water-filled pores.59,60 These pores alter the permeability to ions and
depolarize the membrane.59,60 In one proposed mechanism, magainin 2 becomes α-helical in the presence
of the lipids and forms a pore, lipid flip-flopping occurs, and peptides enter the periplasmic space to target
the inner membrane, alter both lipid asymmetry and cause depolarization of the membrane.59,60 Similarly,
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A

B

C

Figure 3. Models of how membrane disruption can occur, where the blue rods represent the peptides and
the lipid heads are orange (A) carpet model (B) toroidal pore model (C) barrel-stave model

melittin (GIGAVLKVLTTGLPALISWIKRKRQQ), a 26-AA peptide that makes up 50% of the dry
weight of honey bee venom, is highly membrane lytic against bacterial and mammalian cells.53,56 This
peptide, derived from the European honeybee (Apis melifera) forms an amphipathic helix, has a net
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charge of +6, and a hydrophobic C-terminus comprised of KRKR.56 A proline in the middle of the
sequence causes a break in the peptide structure, but it is still α-helical overall.56 Melittin and the related
alamethicin are classified as peptide toxins due to their strong lytic abilities, with membrane
depolarization being their major mode of action.42,56 A concentration of 1 μg/mL is sufficient for melittin
to lyse erythrocytes exhibiting its potent lytic ability.56 Although melittin has been labeled a toxin, it has
been utilized for its anti-inflammatory61 and anti-cancer53 properties indicating that whether peptides are
very hemolytic or toxic to human cells they can still be used for human applications. Ixosin
(GLHKVMREVLGYERNSYKKFFLR), another membrane targeting AMP, has a different mechanism
of action. Ixosin is a peptide from the salivary glands of Ixodes sinensis, a hard tick.20 The mechanism of
action against G(-), G(+) bacteria, and fungi, is pore formation and the oxidization of lipids, through an
ATCUN motif.20,48 In addition, ixosin exhibited synergistic activity with ixosin B, another antimicrobial
peptide from ticks, due to the localization of the two peptides.48 Ixosin has minimal cell toxicity when
tested with HeLa and HEK293 cells indicating that this could be a potential therapeutic that can utilize
metals already in the human body and have synergistic activity to potentiate activity.48
Intracellular targeting has also been observed with numerous peptides including buforin II62,
indolicidin45,63, tachyplesin I64,65, apidaecin66, and PR-3967. These AMPs have three major targets, which
are DNA, RNA, and protein synthesis. Once inside the cell, there can be specific binding or electrostatic
interactions between positively charged AMPs and negatively charged DNA and ribosomes. Peptides
with a high content of specific residues, such as proline and arginine, tend to enter cells easily and have
intracellular mechanisms.67 Two modes of translocation have been demonstrated with some AMPs that
spontaneously translocate or those that can utilize proteins to transport into the cell. One peptide that can
spontaneously translocate is buforin II (TRSSRAGLQFPVGRVHRLLRK), which was isolated from the
N-terminus of the histone H2A from the stomach of Bufo gargarizans and was found to be highly active
against fungi as well as G(+) and G(-) bacteria.68 This 21-AA peptide exhibited no cell lysis even at 5X
MIC, indicating a purely intracellular mechanism with high affinity DNA and RNA binding.68 Even at
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sub-MIC concentrations the peptide was able to translocate the cell membrane without causing membrane
defects or using proteins to translocate.68 The C-terminus of buforin II contains the DNA binding moiety
and is α-helical in solution with a proline hinge in the middle of the peptide giving a unique helix-hingehelix structure that contributes to its wholly intracellular mechanism because proline residues cause a
rigidity due to the ring structure that is not seen with any other AAs.19 Another peptide capable of
translocating is indolicidin (ILPWKWPWWPWRR), a 13-AA peptide isolated from bovine neutrophils,
that is tryptophan- and proline-rich and exhibits an extended structure in the presence and absence of
lipids.41,45 Indolicidin was able to permeate the outer and inner membrane of E. coli within minutes of
interaction with the membrane but no cell lysis has been observed, even when tested at 3X MIC.45,63
Further analysis of the mechanism revealed that indolicidin causes filamentation or elongation of E. coli,
which is indicative of inhibition of DNA synthesis.63 Not only does indolicidin inhibit DNA synthesis, it
also inhibits DNA processing enzymes, binds directly to abasic DNA sites, ssDNA, and dsDNA, and
causes DNA crosslinking.69,70 These errors can result in loss of DNA replication abilities.69,70 At high
concentrations, indolicidin appeared to halt protein synthesis within five minutes of incubation, though
this seemed to be secondary to inhibition of DNA synthesis.63
The target of an AMP can also change with increasing concentration, which is not uncommon for
AMPs. One such case is with tachyplesin I (KWCFRVCYRGICYRRCR), a 17-AA AMP, which was
isolated from hemocytes of the horse shoe crab Tachypfeus tridentatus.18 The peptide structure was
elucidated by NMR spectroscopy and has a unique antiparallel β-sheet structure with two disulfide bonds
and distinct hydrophobic/hydrophilic sides indicating an amphipathic structure.71 Tachyplesin I is active
against G(-) and G(+) bacteria, but the mode of action of tachyplesin I has been debated in the past. It has
been observed to act on intracellular targets, 65,71,72 have a high affinity for binding LPS,18 and other
membrane disruption properties.72,73 It was demonstrated to bind at the minor groove of DNA when the
disulfide bonds are intact indicating the importance of the rigid β-sheet structure in the DNA binding
abilities.65,71 Recently, it was determined that tachyplesin I has a concentration dependent mechanism
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because while membrane disruption seems to be the primary target, sublethal doses can influence the
esterase activity of bacteria and cause cell death.72,73 Tachyplesin I in a β-sheet has also been seen to form
anion selective pores that allow the internalization of approximately 200 peptides.74 It is suspect whether
DNA interactions occur intracellularly because of the reducing environment inside of the cell and the
necessity for the cysteine bonds to allow for DNA binding.
Other AMPs use transporter channels to enter the cells rather than being able to translocate to the
inner membrane. Apidaecin (GNNRPVYIPQPRPPHPRL), a proline- and arginine-rich peptide, has a
stereospecific mechanism of action.75 This peptide can translocate without causing cell lysis and it has
been postulated that it uses transporters to enter the cell.66 While most AMPs activity is unaffected by a
change from L to D AAs, apidaecin has a complete loss of activity when made with D form AAs,
indicating that the target has some specificity for binding.75 It was found that protein synthesis was the
target of apidaecin and that it was most likely binding to ribosomes to inhibit protein synthesis.66
Apidaecin also binds bacterial Dna K, a heat shock protein, with sequence specificity, while it
nonspecifically binds the chaperone GroEL.76 Interestingly enough, the peptide did not interact with
HSP70, the Dna K analouge in human cells, and seemed to specifically target and inactivate bacterial Dna
K indicating the potential for this peptide as a therapeutic agent.76 Apidaecin interacts with LPS by
binding to chaperone proteins, the peptide may potentially transport to the inside of the cell where it could
bind to DNA and ribosomes to inhibit growth.66,76 Another peptide rich in proline and arginine residues,
PR-39 (RPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP), also has intracellular activity mediated by
active transportation to enter the cell.67 PR-39 is a 39-residue peptide that is comprised of almost 50%
proline residues.67 It enters the cell after eight minutes and kills 75% of cells within three minutes of
incubation by inhibiting DNA synthesis and causing protein degradation.67 SbmA is an inner membrane
protein in E. coli that is likely part of an ABC transporter that proline rich AMPs, such as PR-39, can use
for transport into cells.77 PR-39 and other proline-rich AMPs use this inner membrane protein to enter the
cell and bind their intracellular targets.77
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AMPs can utilize different modes of action whether it be multiple membrane or intracellular
targets that lend them to become alternatives to modern ABXs. In addition to this, they have also
appeared in several cases to be selective for pathogenic membranes indicating selectivity that is crucial to
therapeutic development. AMPs have shown that they can be used in combination with each other, as in
the case of ixosin, or can be used synergistically with ABXs.32,33 Moreover, AMPs can utilize metal ions
that are already abundant in the human body to potentiate greater activity on pathogens.36,48 The variations
in AA composition and secondary structure shows that hundred and thousands of combinations can be
synthesized, including the addition of DNA or protein binding moieties that can kill cells based on
different and specific mechanisms that will be difficult for the bacteria to confer resistance to. AMPs have
great potential to be a novel class of drug molecules.
1.4 Piscidins and gaduscidin-1 as therapeutic AMPs
Recently, a new group of piscidins were isolated named the gaduscidins that have multiple metal
binding motifs and represent a unique facet of the piscidin family, as most piscidins have no metal
binding motif or they only have an ATCUN motif. The piscidins are a class of α-helical, histidine-rich
AMPs from teleost fish that were originally isolated from mast cells of hybrid striped bass (Morone
saxatilis x M. chrysops).78 The isolation of the piscidins was the first report to find AMPs in
immunologically relevant cells.78 Three piscidins were recovered and named piscidin-1, -2, and -3 (p1,
p2, p3).78 The piscidins were originally found in mast cells but were later isolated in granules as well.
Interestingly, the piscidins were later isolated in granules but were not found in phagosomes.21 The
peptides were transported to the phagosomes instead, suggesting extracellular and intracellular killing
abilities of piscidin.21 The peptides were found to be moderately hemolytic, with broad spectrum activity
against fish pathogens and parasites25,27,28, human related pathogens78, fungi22,79, and viruses24 that retained
activity even in high salt conditions.25 The sequences of these piscidins (Table 1) show a highly conserved
N-terminus with H, F, and I residues, where p2 is identical to p1 with the exception of an R to K
mutation.78 All three piscidins have an ATCUN and an HH or a bis-H motif. Natural piscidins exist as a
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Table 1. Summary of selected peptides in the piscidin family with all H residues in bold
Peptide

Sequence

Piscidin-1

FFHHIFRGIVHVGKTIHRLVTG

Piscidin-2

FFHHIFRGIVHVGKTIHKLVTG

Piscidin-3
Piscidin-4
Gaduscidin-1
(pis-1)
Gaduscidin-2
(pis-2)
Pis-2β

Organism

Accession
Number

FIHHIFRGIVHAGRSIGRFLTG
FFRHLFRGAKAIFRGARQGXRAHKVV
SRYRNRDVPETDNNQEEP

Morone saxatilis x M.
chrysops
M. saxatilis x M.
chrysops
M. saxatilis x M.
chrysops
M. saxatilis x M.
chrysops

L0CKG3-1

FIHHIIGWISHGVRAIHRAIH

Gadus morhua

D4HRB8

FLHHIVGLIHHGLSLFGDRAD

G. morhua

E2EZU3

Q8UUG0
Q8UUG2
P0C006

FLHHIVGLIHHGKLDMYRSNN

G. morhua
E7D8W6
Pleuronectes
Pleurocidin
GWGSFFKKAAHVGKHVGKAALTHYL
americanus
P81941
Epinecidin-122–42
FIFHIIKGLFHAGKMIHGLV
Epinephelus coioides
Q6JWQ9
Myxinidin
GIHDILKYGKPS
Myxine glutinosa L.
--Dicentracin
FFHHIFRGIVHVGKSIHKLVTG
Dicentrarchus labrax
P59906
Chrysophsin-1
FFGWLIKGAIHAGKAIHGLIHRRRH
Chrysophrys major
C3KHI8
Chrysophsin-2
FFGWLIRGAIHAGKAIHGLIHRRRH
C. major
P83546
Chrysophsin-3
FIGLLISAGKAIHDLIRRRH
C. major
P83547
TP1
FDWDSVLKGVEGFVRGYF
Oreochromis niloticus
I3KPK0
TP2
GECIWDAIFHGAKHFLHRLVNP
O. niloticus
L0CKQ8
TP3
FIHHIIGGLFSVGKHIHSLIHGH
O. niloticus
L0CMD2
TP4
FIHHIIGGLFSAGKAIHRLIRRRRR
O. niloticus
L0CKG3
TP5
QLQGKQVSGEVVQKVLQELIQSVAKP
O. niloticus
L0CM08
25
mixture of amidated and nonamidated forms of peptide. The effect of nonamidated versus amidated p1
and p3 were examined via multiple techniques including NMR spectroscopy, and it appears that
amidation did not change the α-helicity of the peptide or the perpendicular orientation of the peptide to
the PC/PG lipid bilayer.25 The structure of p1 was determined by NMR in the presence of trifluoroethanol
(TFE) and showed an α-helical conformation from residues 8 to 17 with disordered N- and C-termini.80
This study also used a mixture of lipids, with 20% of them being negatively charged to induce a pseudoG(-) membrane, and found that p1 did not induce any voltage-dependent channels indicating that the
barrel stave model is not consistent with the data while the toroidal pore model better explains the
mechanism of p1 and p2.80 Extracellular and intracellular mechanisms, such as nuclease activity, have
been observed for p1 and p3.81 When compared against E. coli persister cells and biofilms, p3 was more
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active than p1 due to the nuclease activity of p3, while p1 is more membranolytic.81 Comparing p1 and
p3, p1 was seen to be more antimicrobial and more hemolytic than p3 when tested against G(+) bacteria.82
Potent antifungal activity was observed for p1 and p3 and they were more active than amphotericin B, an
antifungal ABX, when tested against Trichosporon beigelii and Candida albicans79. It was found that p1
acted against the fungi by disrupting the membrane via pore formation.79 Comparatively, p2 was found to
be active against water mold, multiple parasites, and to have partial synergism with Cu2+.25,26 It was also
observed to be active against multiple types of fungi including C. albicans via a pore formation
mechanism22 and has been reported to have synergy with a hepcidin peptide that was also isolated from
hybrid striped bass gills83.

Figure 4. (A) Piscidin alignment of mature peptide sequences, showing conserved residues. Accession
numbers are as follows: p1 Q8UUG0, p2 Q8UUG2, dicentracin p3 P0C006, Gad-1 D4HRB8,
Chrysophsin-1 P83545, Chrysophsin-2 P83546, Chrysophsin-3 P83547, Epinecidin-1 Q6JWQ9, Gad-2
E2EZU3, Pis-2β E7D8W6, Pleurocidin P81941, TP4 L0CKG3, TP3 L0CMD2
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Later, piscidin 4 (p4) was isolated from mast cells of M. saxatilis x M. chrysops.84 This piscidin is
44-AAs long, twice the length of the other piscidins, and unlike the others, it only weakly formed an αhelix.84 The sequence varied as well with the peptide having a hydroxylated W in position 2084 and only
two H residues. Similar to p1, p4 showed leakage from vesicles indicating that its likely target is the
membrane and that potentially the toroidal pore model may be the mode of action of p4.85 The hemolytic
ability of p4 is lower than its active concentration against human and fish pathogens.84,85
Since the elucidation of the first piscidins, multiple others have been identified from teleost fish,
more specifically from the Perciformes order.78,27 The piscidin family is comprised of other AMPs
including pleurocidins, moronecdins, gaduscidins, myxinidin, epinecidin, chrysophsins, and dicentracin
(Figure 4). The aforementioned piscidin peptides have shown potent broad spectrum activity and have
high H content with several of them having ATCUN motifs that potentiate their activity.86 The different
piscidins are 12 to 44 AAs and can have low sequence homology to each other but are all α-helical to
some extent. The piscidin family are characterized by a four exon/three intron gene sequence, with few
exceptions, and a highly conserved N-terminus with H, F, and I residues, as well as a highly conserved
propeptide region (Figure 5).28 Recently, nile tilapia (Oreochromis niloticus), a teleost fish, has been
found to produce a total of five piscidins named TP1-TP5.29 These peptides range from 18 to 26 residues
with TP3 and TP4 having high sequence homology to the original piscidins with multiple H residues and
a conserved N-terminus with I and F residues.29 TP4 is the most active peptide out of the group, with TP3
and TP4 exhibiting activity against G(-) and G(+) bacteria while TP2 and TP5 showed no activity.29 All
five were predicted to be α-helical and TP2, 3, and 4 were mildly hemolytic against tilapia erythrocytes
with TP3 and TP4 being the most hemolytic and TP1 and TP5 not exhibiting hemolytic activity.29 TP3
may have anti-cancer properties and was deemed not harmful to normal mammalian cells, therefore
indicating the potential of TP3 to be an anti-cancer agent.29 TP2, 3, and 4 were all isolated in
immunologically relevant tissues in the fish, again showing similarity to the original piscidins.29 TP3 was
the only peptide found in the gills while TP2 and TP3 were both found in the head

Figure 5. Alignment with the full prepropeptide region of the piscidins with their available accession numbers,
excluding p3, myxinidin, and chrysophsin 1-3 due to the lack of the full peptide sequence
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kidney, as well as the epidermis, with TP2 also being found in the spleen.29 TP4 was the only AMP found
in the intestine, while TP1 and TP5 were not able to be immunostained, therefore it is not clear what their
role is.29 Under bacterial challenge, TP4 expression was increased 10 to 60 fold in the head kidney, gills,
and spleen.29 TP2 and TP3 were not seen to be upregulated, indicating the importance of TP4 to the
overall immune response of the tilapia.29
TP4 was further investigated by multiple groups, which yielded an NMR structure elucidating the
importance of the F, I, and L residues in the center of the peptide for the formation of an α-helix.87 The
peptide has a hydrophobic core at the N-terminus with a cationic C-terminus being important for
interactions with bacterial membranes and a central α-helix.87 This is interesting because the piscidins
have conserved these residues throughout, giving more evidence for their need towards the
amphipathicity and subsequent activity of the peptide. The authors also showed that when the bis-H motif
at the third and fourth position were substituted for A residues there was a loss in fungal activity, but the
peptide still retained hemolytic activity when tested with mouse erythrocytes, potentially pointing to the
need of the conserved bis-H motif for fungal applications.87 The antimicrobial ability of the peptide with
the A substituted third and fourth position, shows that the activity against MRSA and P. aeruginosa was
abolished while the S. aureus MIC increased 4-fold when compared to the wild type (WT) peptide.87
The original piscidins were also independently isolated peptides from the epidermis and gills of
M. saxatilis x M. chrysops by Lauth et al. and were named moronecidins.88 These two peptides are
identical to the sequences of p1 and p2 with an additional T residue at the C-terminus of the peptide
making them 23-AA peptides.88 The two C-terminally isoforms were also seen to be α-helical and have
activity against fungi and G(-) and G(+) bacteria including MRSA, with activity in the presence of high
salt content.88 Another peptide with high sequence homology to p1 and p2 is dicentracin, which was
isolated from head kidney leukocytes of the sea bass Dicentrarchus labrax.89 Interestingly, dicentracin
showed ~90% sequence homology with p1 and p2 with the only difference from p1 being a S in place of
the T in the 15th position and a 40-68% homology of the propeptide regions.89 Dicentracin has an ATCUN
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motif, however, the activity with and without Cu2+ has not been studied. Experiments show that after 24
hours of acute stress there were increased levels of peptide in the gills, and to some extent the epidermis,
confirming that the peptide has a role in stress and immunological response though the activity of this
peptide has not been extensively studied.90
Another piscidin with an ATCUN motif is myxinidin, which was isolated from Myxine glutinosa
L. or hagfish.91 Although there are conflicting reports on the activity of this peptide92, it has been reported
to be active against G(-) and G(+) bacteria, fungi, and fish pathogens.91 This peptide is substantially
shorter than other piscidins (12-AA residues) but is similar to other piscidins in that the activity is not
abolished in the presence of up to 300 mM NaCl.91,93 Myxinidin has therapeutic potential, because it was
not hemolytic when tested with rabbit91 and human erythrocytes.93 There was also low toxicity when
tested on mammalian cells.94 The peptide was found to be partially α-helical, from residues 2-9, by NMR
spectroscopy and circular dichroism (CD).93,94 A second study used an alanine walk (an A is substituted
for each AA for a total of 12 mutants) to probe the essential residues.94 All mutants were ~60% helical in
TFE indicating that there was no dramatic change in the secondary structure based on the single AA
substitutions.94 The results showed that the G1, P11, and S12 residues ranked the highest in importance
for the activity of the peptide.94
Pleurocidin is one of the largest groups of the piscidin family with the first pleurocidin being
isolated from winter flounder, Pleuronectes americanus.95 It was found to be prevalent in the mucous
membranes of the fish95 and was found to be produced in goblet cells of the small intestine.32
Immunostaining revealed that the peptide is located in the eosinophilic granular cells that are transported
to inflammation or injury sites as a non-specific defense in the gills.96 The pleurocidin gene has four
exons and three introns32, like the piscidins, and was observed to kill bacteria in up to 625 mM NaCl.95
Consistent with other piscidins, the peptide was α-helical in the presence of membranes57, with broad
spectrum activity95, including activity against clinical fungal isolates.32 It is suggested that activity against
C. albicans is mediated by the formation of ROS and the eventual membrane depolarization of
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mitochondria, which then leads to the expulsion of pro-apoptotic factors and eventually apoptosis of the
cell with either direct or indirect DNA damage.23 Pleurocidin had stronger interactions to anionic lipids
rather than neutral lipids, indicating some selectivity for bacteria.57,97 Dye leakage was exhibited in the
presence of a neutral and negatively charged lipid mixture (PC/PG) that would mimic G(-) bacteria.97
NMR studies revealed in plane alignment with the lipids similar to magainin 2.97 The fully protonated
histidine-rich peptide, where the charge increased from +5 to +8, was also studied by NMR, however, the
results showed no change in membrane disruptive activities indicating that the presence of H is likely not
related to increased membrane disruption at a lower pH.97
Additionally, there are multiple isoforms of chrysophsin, a piscidin, that were isolated from
granule cells in the gills and epithelial cells of Chrysophrys major or red sea bream.98 All of the peptides,
named chrysophsin -1, -2, and -3, are C-terminally amidated and range from 20 to 25 AAs in length.98
They all exhibit an α-helical conformation in the presence of a membrane mimetic solvent and a
disordered structure in water.98 These peptides are similar to p1-p3 in that they are hemolytic to human
erythrocytes.98 They are active against G(-) and G(+) bacteria and chrysophsin-3 was tolerant to up to 160
mM NaCl where the other two could withstand 320 mM salt and remained bacteriocidal.98 A unique and
conserved feature is the RRRH sequence at the C-terminus of the peptide.98 Chrysophsin-1 showed a
mechanism of pore formation, which was enhanced with negatively charged lipids.99 When tested against
human lung fibroblast cells, chyrsophsin-1 was highly toxic, but less so without the RRRH motif, which
was found to be important for α-helix formation and pore formation.99 Chrysophsin-1 has also shown
activity against numerous oral pathogens such Enterococcus faecalis, Actinomyces viscous, and
Streptococcus mutans biofilms, which were thinned after exposure and 90% of cells were killed within
four hours of incubation.100 Anti-cancer properties by lysing membranes has also been reported.30
Chrysophsin-1 has been observed to have anti-inflammatory properties by inhibiting TNF-α secretions
that normally lead to inflammation, which has not been observed with piscidin.30
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Potentially one of the most studied and longest piscidins is epinecidin-1, which is 67-AAs and is
commonly truncated to a 21-AA segment.101 It was found to localize in the head kidney, epidermis, and
intestines of the orange-spotted grouper fish Epinephelus coioides.102 Similar to other piscidins, the gene
sequence consists of three introns and four exons and had activity against G(-) and G(+) bacteria, fungi,
and yeast.101 The peptide is not hemolytic towards tilapia erythrocytes but are hemolytic to human
erythrocytes.103 Epinecidin-1 can be a powerful therapeutic in humans and fish, this being exemplified by
increased immunity to Vibrio vulnificus in fish after one injection of epinecidin-1.102 In addition to
affording protection to fish, a study investigated protection against P. aeruginosa infection in mice, which
can cause septic shock.103 The authors found that a dose of 0.005 mg/g protected the mice from sepsis,
and the peptide showed no toxicity to the mice even at high concentrations such as 50 mg/kg where other
AMPs have been seen to be toxic in mice.103 Moreover, there was a 100% clearance of MDR P.
aeruginosa within 48 hours of peptide administration and the peptide affected expression of other genes
such as interleukins and interferons, which modulate the immune system.103 Additionally, it was
postulated that the peptide binds LPS and blocks cytokines, such as TNF-α, and reduces endotoxin release
and inflammation in the mice similar to the chrysophsin family of peptides.103 Epinecidin-1 was also
found to have anti-cancer properties by disrupting the membrane and having lytic activity against HT1080
and HeLa cells at 2 µg/mL.104 Epinecidin utilizes pore formation and can potentially trigger apoptosis via
a pathway different from caspase, which is traditionally targeted by anti-cancer drugs and rather
specifically targets necrosis gene expression.104 Epinecidin-1 is also active against MRSA.105 Mice studies
have reported that the peptide not only reduced the bacterial count of MRSA more effectively than
vancomycin in an open wound but also helped to induce wound healing and reduced the expression of
inflammatory cytokines.105 An additional study was repeated using a pig model in vitro and showed
similar results indicating that epinecidin-1 could be a potential clinical option for treatment of MRSA.106
Additionally, activity was seen against Propionibacterium acnes, C. albicans, and Trichomonas vaginalis
indicating larger therapeutic applications including use in creams and topical medications.107
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Overall, the piscidin family has yielded multiple AMPs that can be used as therapeutic agents in
both fish and human. The therapeutic value of these compounds is enhanced by the presence of metal
binding motifs, especially in the presence of both the ATCUN and HXXXH motifs. Gaduscidin 1 (gad-1)
specifically has both of these motifs and has not been extensively studied. Gad-1 is a piscidin AMP that
originated from Atlantic cod (Gadus morhua).86 It was reported by two groups independently with its
paralogue and a splice variant, gad-2 and gad-2-β (alternatively named pis1, pis2, and pis2-β). 28,86 Gad-1
(FIHHIIGWISHGVRAIHRAIH, Figure 6) is found in immunologically relevant tissues of G. morhua
such as the mucus membranes, gills, spleen, and head kidney.108 In addition to immunological tissues,
gad-1 was isolated in the swim bladder and kidneys, which are implicated in osmosis and buoyancy rather
than immune response.108 Gad-1 is found in oocytes and in low levels in the brain, indicating a potential
role in cell development or tissue repair.86,108 This tissue dispersity could imply that gad-1 does more than
just protect the fish against pathogens. G. morhua has a unique immune system in that they produce no
MHC class II, CD4, and invariant chain, all important to the adaptive immune system.109 Therefore,
AMPs including the gads, hepcidin110, β-defensins111, and codCATH112 are crucial to the immune system
of these fish. The presence of gad-1 in organs that interface water including the mucus membranes and
gills, show great importance in protecting the fish before and after an infection occurs.
Gad-1 has a 50% sequence homology to p1 and a 45% sequence homology to both p2 and p3.
Interestingly, a sequence alignment with several piscidins shows that H3, H4, H11, and H17 are all
conserved residues (Figure 4). The sequence of gad-1 is also similar to TP4 due to the bis-H motif in the
third and fourth positions and the H17 and R18 arrangement at the C-terminus of the peptide. Gad-1 is
one of the only piscidins, with the exception of pleurocidin and chrysophsin 1 and 2, to have a W residue.
The sequence is also similar to p3 in respect to the R residues in position 14 and 18 and the N-terminus of
FIHH is only seen with gad-1, TP3, TP4, and p3. Again, similar to other piscidins, there is a three
intron/four exon gene sequence.28
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Figure 6. (A) Helical wheel diagram of gad-1 and (B-D) I-TASSER predictions on the structure of gad-,
where blue denotes the C-terminus and red denotes the N-terminus
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The mechanism has not been elucidated for gad-1, however it has been suggested that it is
membrane disruption.113 Gad-1 has been seen to have broad spectrum antimicrobial activity28,113 but did
not have antiparasitic activity, while its paralog gad-2 was active against Tetrahymena pyriformis
implicating their different roles in the immune response.28 Intriguingly, the activity of gad-1 does not
increase with a decrease in pH unlike many other histidine containing AMPs.113 It has been suggested that
because the charge of the peptide does not change substantially (+3 to +8) that this is the reason there is
no change in activity at pH 5, which is similar to pleurocidin.113 Gad-1 contains a total of five H residues
including an HXXXH and an ATCUN motif, both associated with metal binding and potentiating activity
against pathogens. Gad-1 is one of the only known piscidins with both of these motifs. Our interest on
this peptide was due to the metal binding motifs and how gad-1 is utilized in the natural defense of G.
morhua. Gad-1 exhibits an almost perfect amphipathic helix, which unfortunately has been correlated to
higher hemolysis activity against erythrocytes.113 The metal binding activity of gad-1 has never, to our
knowledge, been studied, while the role of histidine in the peptides have been studied using molecular
dynamics (MD).114
Previous MD studies of gad-1 reveal that H3 and H4 are important to lipid interactions.114 When a
pore is formed H17 and R18 interact with the planar part of the bilayer.114 No implications for H11 or
H21 were revealed with MD studies. The N-terminus, where there is less helical content, also had a
greater tendency to interact with the pore than the C-terminus when the H residues are not protonated.114
If protonated, H3 interacts solely with the rim of the lipids in the pore, which reinforces the importance of
the N-terminal H residues.114 The bis-H motif may have affinity for close proximity to lipid bilayers,
whether they are charged or not.114 An NMR study was conducted and showed H21 is not in the helical
region of the peptide and that there is a helix break from residue 9 to residue 12 which corresponds to S10
and H11.113 The MD and NMR studies did not consider the Cu2+ bound state of the peptide or investigate
any metal binding activity with Cu2+ or Zn2+.
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CHAPTER 2
Investigating gad-1 for metal ion binding and antimicrobial applications
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2.1 Introduction
Herein, gad-1 metal binding abilities were examined along with the role of H in potentiating
antimicrobial efficacy. A set of modified peptides, where each H was substituted for an A, was
synthesized (Table 2). The Cu2+ and Zn2+ binding of gad-1 were studied using spectroscopic techniques

Table 2: Summary gad-1 mutant peptides
Peptide
Gad-1
H3A
H4A
H11A
H17A
H21A

Sequence

FIHHIIGWISHGVRAIHRAIH
FIAHIIGWISHGVRAIHRAIH
FIHAIIGWISHGVRAIHRAIH
FIHHIIGWISAGVRAIHRAIH
FIHHIIGWISHGVRAIARAIH
FIHHIIGWISHGVRAIHRAIA

and mass spectrometry with the mutant peptides to determine how each H may play a role in metal
binding. The antimicrobial activity the mutant peptides against G(+) and G(-) bacteria that include fish
and human pathogens, were determined. H3 proved to be important to the activity of gad-1, as without it
Cu2+ cannot be bound and the ATCUN motif is rendered inactive. H17 also showed importance to the
activity of the AMP while H4 and H21 did not have as much of an effect on the activity based on MIC
measurements with a multitude of pathogens, except for the exception of Vibrio spp. with H4A. Previous
MD studies showed substantial interaction of the lipid bilayer with the H4, therefore it is interesting that
the activity of the H4A mutant is not markedly different from the WT peptide.
The antimicrobial mechanism was explored and was determined to be membrane disruption with
no suspected intracellular activity. A β-galactosidase leakage assay showed that the induced leakage from
cells for all mutants were ~50% the amount Triton X-100 showing that pores were formed. Another
interesting facet of the mechanism is that gad-1 could peroxidize lipids at a significantly higher rate when
Cu2+ was present. It was shown that the H3A mutant did not significantly increase the rate of lipid
peroxidation when Cu2+ was added, indicating that the ATCUN motif is responsible for some of the lipid
peroxidation activity. It was concluded that gad-1 was able to bind Zn2+ with very low affinity to the
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HXXXH motif, but this site may be another potential Cu2+ binding site. The α-helicity of gad-1 and the
mutants were characterized using CD. Moreover, the hemolysis to human erythrocytes of the peptide and
mutants were found to probe the possibility for using gad-1 as a therapeutic for human usage. Other
potential applications for gad-1 would be to use it in farm fish feed, as it was shown previously that gad-1
is not hemolytic to cod erythrocytes28, as well as using transgenic plants115 and fish116 to boost their
immune system. Atlantic cod is a very economical fish especially in Norway, where farms are often
decimated by fishborne illness caused by a variety of pathogens.108,111 This can have major economic
impact and an impact on the general public, as if they consume the fish they can also become ill. The
major pathogens are Vibrio and Aeromonas species that are both found in brackish water and can cause
necrotic tissue damage and hemorrhaging to the fish.117 If other fish have open wounds they will be easily
infected by the pathogens and spread to the blood and cause septicemia.117 Gad-1 could be utilized in fish
farms to reduce the spread of infection to other fish and humans, as well as therapeutic applications for
human infection and disease.

2.2 Metal ion binding
Several peptide mutants of gad-1 (Table 2) were synthesized to determine the role of H in metal
ion binding of gad-1. Gad-1 has both an ATCUN motif and an HXXXH motif that can bind to Cu2+ and
Zn2+, respectively. To elucidate whether gad-1 binds to Cu2+ and Zn2+ and the residues involved in
binding, MS was used. The peptides were incubated with varying ratios of Cu2+ to determine whether
binding occurs and the stoichiometry of binding. Gad-1 was assumed to bind at least one Cu2+ ion due to
the presence of the ATCUN motif. After injecting the peptide sample with different ratios of Cu2+, it was
shown that there was binding to at least two sites in the WT peptide based on the masses (Figure 7, Table
3). When 2 equivalents of Cu2+ was added, the [G1-3H+] and [G1-4H+] peaks, where G1 is gad-1, had
similar intensities to the masses corresponding to one Cu2+ being bound to gad-1. There were also smaller
peaks correlating to gad-1 with two Cu2+ ions bound, which intensified when 5 equivalents of Cu2+ was
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Figure 7. MS data indicating that two Cu2+ ions bind to gad-1 (A) gad-1 with no added Cu2+ (B) gad-1 with 1X Cu2+ (C)
gad-1 with 2x Cu2+ (D) gad-1 with 5X Cu2+
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Table 3: Summary of apo-gad-1 and bound-gad-1 masses, where black indicates apo-gad-1, red indicates
one Cu2+ or Zn2+ bound, and blue indicates two Cu2+ bound
Sample
Mass Expected (Da)
Mass Observed (Da)
Gad-1
1X Cu2+
2X Cu2+
5X Cu2+
5X Zn2+

1236.0, 824.3, 618.5, 495.0
1267.3, 844.8, 633.6, 506.9
1299.0, 866.0, 649.5, 519.6
---1267.3, 844.8, 633.6, 506.9

1236.4, 824.4, 618.8, 495.0
1235.9, 844.9, 824.4, 634.1, 618.5, 507.3, 494.9
1236.4, 866.0, 844.6, 824.2, 649.0, 634.0, 618.6, 507.5, 494.8
1266.2, 1236.0, 866.0, 845.0, 824.2, 648.8, 634.0, 521.6, 507.1, 494.8
1236.5, 845.0, 824.5, 634.1, 618.9

added. The second binding site is assumed to be the HXXXH motif due to the spacing of the H residues
in the helix and the affinity of H to binds Cu2+. Several attempts to visualize the Cu2+ bound in a square
planar manner were made, as a peak at 525 nm has been observed with many ATCUN peptides.46 The
concentration of gad-1 was varied from 0.3 mM to 1 mM and Cu2+ and was titrated in H2O (data not
shown) and buffer solutions (Figure 8). No peak was observed, however this is not uncommon and could
be due to the high peptide concentration that may cause aggregation. The appearance of a peak was seen

Figure 8. Cu2+ titration with 1 mM gad-1 in 75 mM HEPES and 100 mM NaCl
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around 750 nm that needs to be investigated further. It is unclear what this peak is because it continues to
grow even after 2 equivalents of Cu2+ was added.
It was also observed that the HXXXH site may not have a high affinity for binding to Zn2+. MS
data showed low intensity Zn2+ bound peptide with 5X Zn2+ concentration (Figure 9). In addition to this, a

A

B
A

Figure 9. MS data indicating that one Zn2+ ion binds to gad-1 with low affinity (A) gad-1 with no added
Zn2+ (B) gad-1 with 5X Zn2+
competitive binding assay with zincon was performed to analyze whether the peptide had higher binding
affinity for Zn2+ than zincon, which has a Kd of 12.6 μM.118 It was found that this was not the case, as
titrating Zn2+ into peptide solution with equimolar amounts of zincon did not inhibit zincon binding
(Figure 10). MIC data with gad-1 and added Zn2+ also yielded negative results showing that the activity of
gad-1 with Zn2+ did not improve more than the WT. Again this shows that Zn2+ is potentially not bound
by the peptide in a meaningful way. This data indicates that the Zn2+ can bind to gad-1 if there is a high
concentration of metal ions, however, in vivo this may not be the case, as there was no increase in
antimicrobial activity. The Irvings-Williams series explains that Cu2+ complexes have a greater stability
than Zn2+ complexes, which can clarify why Cu2+ may preferably bind in the HXXXH position and
potentiate activity in vivo.119
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Figure 10. Competitive Zn2+ titration with zincon and gad-1

2.3 Secondary structure determination
The secondary structure of the peptides were analyzed, along with apo-gad-1 and gad-1 in the
presence of Cu2+ and Zn2+ ions, using CD spectroscopy. Figure 11 shows the CD spectra for the peptides
in H2O and in a mixture of TFE and H2O. In H2O, all of the peptides display a disordered structure
indicated by the minima at ~200 nm and the maxima at ~190 nm. The peptides in the presence of 50%
TFE, a membrane mimetic solvent, exhibit double minima at 222 and 208 nm with maxima at ~195 nm;
therefore, an α-helical conformation is induced in the presence of a membrane mimetic solvent. This is
consistent with existing data on gad-1 that reported an α-helical structure in membrane mimetic solvent
based on CD and NMR spectroscopy experiments.113 The switch from a disordered to an α-helical
structure in the presence of membranes is consistent with other known AMPs such as magainin 2.17 The
degree of helicity was calculated for each peptide using equation 2. Table 4 shows that H4A and H21A
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A

B

Figure 11. CD data (A) peptides in H2O (B) peptides in 50% TFE solution
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Table 4: Summary of percent helicity in 50:50
TFE:H2O
Peptide
Percent Helicity
Gad-1
42.72
H3A
45.93
H4A
18.90
H11A
57.14
H17A
51.33
H21A
19.54
had the lowest degree of helicity followed by gad-1. H3A, H11A, and H17A were the most helical
structures. The degree of helicity of gad-1 does not match previous data from Booth et al. who reported
that gad-1 was 100% helical in the presence of 50% TFE at pH 7.113 Based on the helical wheel diagram,
some of these changes in helicity are unexpected. For example, substitution of H21 should not result in a
large change when compared to the WT peptide because it is at the end of the sequence. Additionally, the
substitution of H3, H4, and H17 were expected to yield higher helicity due to the fact that these residues
are surrounded by hydrophobic residues such as F1, W8, V13, and I20. Consequently, the CD data was
collected five times and each time resulted in the same trends in helicity of the peptides.
The secondary structure and helicity of apo-gad-1 and gad-1 in the presence of a membrane
mimetic solvent and metal ions was also investigated (Table 5). Our group has previously shown that
there is not a large change in the CD spectrum or helicity of a peptide when they are metal bound.36
Figure 12 shows the same trend with gad-1, where in the presence of both Cu2+ and Zn2+ at varied
concentrations, there was not a large difference in the spectra or the helicity of the peptide. Overall, the
secondary structure of gad-1 is consistent with previously collected data, indicating it forms an α-helix in
the presence of TFE.
Table 5: Summary of percent helicity in 50:50
TFE:H2O
Peptide
Percent Helicity
Gad-1
Gad-1 with 2X Cu2+
Gad-1 with 5X Cu2+
Gad-1 with 5X Zn2+

42.72
31.22
33.45
39.10
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B

Figure 12. (A) CD data of gad-1 with added Cu2+ (B) gad-1 with added Zn2+
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2.4 Antimicrobial activity
The antimicrobial activity of gad-1 is summarized in Tables 6 and 7. First gad-1 and mutants
were tested on the G(-) fish pathogens V. harveyi and A. hydrophila. Gad-1 showed modest activity
against both pathogens, while the mutants were less effective. The MIC with A. hydrophila showed that
H3 and H17 are essential to the activity because when they were substituted the activity of the peptide
was abolished. The MIC of H11A and H17A was larger than 128 μM indicating clear importance of H11
and H17 in the fish’s natural immunity against Aeromonas spp. Vibrio spp. also showed an overall higher
MIC with the mutants, particularly in the absence of H4, which indicates some importance of this H
against natural pathogens.

Table 6: Summary of MIC values (μM) for gad-1 and mutants (* denotes
only two trials)
Peptide
E. coli
E.coli with
V. harveyi V. harveyi
A. hydrophila
TETA
with TETA
Gad-1
2
16
8
16
16
H3A
16
16
32
128
>128
H4A
2
16
32
32
16
H11A
8
16
*64
-*>128
H17A
8
16
16
*>64
>128
H21A
4
16
16
16
16

Table 7: Summary of MBC values (μM) for gad-1 and mutants (* denotes
only two trials)
Peptide
E. coli
E.coli with
V. harveyi V. harveyi
A. hydrophila
TETA
with TETA
Gad-1
2
16
16
16
16
H3A
16
32
32
128
-H4A
2
32
32
32
16
H11A
8
16
*64
--H17A
8
32
32
--H21A
4
16
32
32
16

Once the potency was proven in fish pathogens, E. coli, a model G(-) bacteria, was tested. Gad-1
against E. coli exhibited high levels of activity with an MIC of 2 µM. H4A and H21A had essentially the
same activity as gad-1, while H17A and H3A were observed to be less active, potentially due to the fact
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that these are the two predicted Cu2+ binding moieties. The MIC with TETA, an extracellular Cu2+
chelator, were also done to show that the low MIC of gad-1 is due to the Cu2+ bound state. WT gad-1 and
all the mutants had an MIC of 16 µM, exactly the MIC of H3A alone with no TETA, indicating that the
Cu2+ bound in the third position is essential for the antimicrobial activity of gad-1.
TKK data using E. coli with 4 µM peptide showed that gad-1, H4A and H11A had similar killing
abilities and were bactericidal at this concentration (Figure 13). H3A, H17A, and H21A mildly inhibited
growth and were bacteriostatic at 4 µM, which is sub-MIC for all three mutants. H4A and gad-1 were

Figure 13. TKK data at 4 μM peptide concentration showing that gad-1, H4A, and H11A are bactericidal
at 4 μM, while the other mutants are bacteriostatic

both above MIC concentrations, while H21A is at MIC concentration, again reinforcing the fact that the
H4 substitution does not seem to affect the activity of gad-1 against E. coli. This data indicates that H3,
H17, and H21 are essential for the bactericidal activity of the peptide.
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2.5 Mechanism of action
Multiple experiments were conducted to elucidate the mechanism of gad-1 and the potential role
of H. First, a β-galactosidase assay was performed to see if the pores can leach β-galactosidase
Table 8: Summary of β-galactosidase
leakage
Peptide
Percent Leakage
Gad-1
H3A
H4A
H11A
H17A
H21A

51.72
51.38
45.47
38.15
39.67
34.18

Figure 14. β-galactosidase data indicating leakage of cellular contents and percent leakage as compared
to Triton X-100
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out of the cell were being made. It was exhibited that at 2 µM concentration gad-1 and all of the mutants
were similarly able to create pores in the cell membrane (Figure 14). In comparison to Triton X-100, the
peptides had about 50% the absorbance which is good considering the low concentration that was being
used (Table 8). This confirms that at least part of the lethality of gad-1 is modulated by pore formation.
The ability to bore holes in the membrane is modulated in part by the amphipathicity of the peptide,
therefore a one AA substitution should not alter the pore forming ability of the peptide drastically.

Figure 15. Lipid peroxidation of E. coli MWF1 with and without added Cu2+ where * is p>0.05 and ** is
p>0.01
The multi-hit nature of AMPs led to the testing of another probable mechanism of gad-1, which
was hypothesized to be lipid peroxidation due to the ROS formation when the Cu-ATCUN complex is
formed. It was shown that ixosin with an H3A mutation was significantly slower than WT ixosin at
causing lipid peroxidation and after one hour peroxidized less than 50% of the WT peptide.48 It is
postulated that gad-1 will have similar activity due to the presence of the ATCUN motif. Using a standard
assay, with ixosin as a positive control, apo-gad-1 and bound-gad-1 were analyzed for quantity of lipid
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peroxidation with the mutants to elucidate which H residues may be necessary for enhanced lipid
peroxidation. Apo-gad-1 and the mutants, with the exception of H11A, were all seen to peroxidize lipids
to some extent (Figure 15), however, when 1 equivalent of Cu2+, was added the amount of lipid
peroxidation increased significantly for gad-1 and H4A, while the difference between the H3A, H17A,
and H21A with and without metal ions was not found to be significant. Cu2+ alone did not elicit any
notable peroxidation when tested at 8 and 16 μM, indicating that if the Cu2+ was not able to bind the
peptide it would not have significantly changed the amount of lipid peroxidation. This result confirms the
importance of the ATCUN motif to modulate higher activity of gad-1. It also confirms that there is little
to no change in oxidizing activity when H4 is substituted. H17A and H21A did not exhibit a statistically
significant change with added Cu2+, which is interesting because this is where the second Cu2+ binding
site may be located. It may be possible that this second binding site is also producing some ROS to
contribute to antimicrobial activity.
2.6 Toxicity
Hemolysis on human erythrocytes was tested to examine if the peptide was selective for bacterial
membranes and whether it may be used as a therapeutic agent in the future. All mutants were ~100%
hemolytic at 4 µM, while gad-1 was about 50% hemolytic at its MIC of 2 µM (Figure 16). A previous
work showed that the toxicity to cod erythrocytes were very low, although they only tested the hemolysis
at up to 2 µM.28 McDonald et al. reported that gad-1 reached 100% hemolysis at 100 µM.113 The
difference in data for the WT peptide can be explained by the method used. The buffer that was used was
slightly different however, the bigger issue is the wavelength at which the plate was read. The Booth
group used 541 nm to analyze the amount of hemoglobin while 414 nm was used in the current assay.
Hemoglobin has two peaks that are both around these wavelengths, however, the peak at ~400 nm is
much more intense, which could be a potential reason as to why the data differs.120
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Figure 16. Hemolysis of gad-1 and mutants tested against human erythrocytes

2.7 Discussion
Based on the evidence presented here, gad-1 seems to utilize Cu2+ to potentiate activity against E.
coli and the mechanism of gad-1 is membrane disruption, coupled with lipid peroxidation. The metal
binding ability of gad-1 was tested with Cu2+ and Zn2+, demonstrating that Cu2+ has two potential binding
sites, while Zn2+ did not bind at an observable amount. In addition to this, when Zn2+ was preincubated
with gad-1 and an MIC was completed, it was seen not to increase or decrease the activity of the peptide,
demonstrating that Zn2+ likely does not have a role in the activity of gad-1.
The secondary structure of gad-1 and the mutants were determined to be disordered in water and
α-helical in the presence of TFE. The percent helicity varied up to 38% between mutants with H4A being
the least helical and H11A being the most helical. Apo-gad-1 and gad-1 in the presence of metal ions
showed little to no change in the CD spectra or helicity of the peptide, consistent with previous reports.
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The CD data showed that if gad-1 is binding metal it does not further stabilize the helix or increase the
helicity of the peptide.
The α-helical nature of the peptide coincides with the high activity of the peptide against E. coli.
Similar to other α-helical peptides, the MIC of gad-1 was in the low μM range. The MIC of the mutants
varied, with the largest change being the H3A substitution which had an 8-fold higher MIC value. This
change is substantial because of the importance of the ATCUN motif for the activity of other peptides that
have been reported and indicates the importance of H3. H4 had the same MIC as gad-1, while H21A was
2-fold higher. H17A and H11A both had 4-fold increases in MIC compared to gad-1. Interestingly, H21A
and H17A could potentially be the second binding site of the peptide indicating importance of both of
these residues in the antimicrobial and metal binding activity. When TETA, a Cu2+ selective extracellular
chelator was added, the MIC of all mutants were equal to H3A, demonstrating that the activity of the
peptide is partially dependent on H3 and Cu2+ binding. Other G(-) bacteria that are natural fish pathogens
were analyzed as well, V. harveyi and A. hydrophila. Gad-1 showed activity against both pathogens.
There was an inhibition of activity with all mutations, indicating that the H residues are important to the
natural immunity of G. morhua, specifically H17 and H3, which had obliterated activity for both
pathogens when compared to gad-1. Overall, the importance of residues H3 and H17, as well as Cu2+
binding was exemplified.
The mechanism of action was elucidated and determined to be the combination of pore formation
and lipid peroxidation. A β-galactosidase assay was used to show that the library of mutants was able to
bore holes in the membrane at a concentration on 2 μM. The efficiency of pore formation was ~50%
compared to Triton X-100 indicating high lytic activity. Another assay to confirm and expand upon the
membrane activity was a lipid peroxidation assay, which has previously been shown to be a mode of
action in ATCUN containing peptides. Apo-gad-1 and Cu2+ bound-gad-1 were significantly different from
each other, where the bound-gad-1 had more lipid peroxidation activity due to ROS formation at the
membrane interface. H4A showed a similar trend when bound to Cu2+, reinforcing that H4 may not be

Portelinha 44
significant for the antimicrobial activity of gad-1 against E. coli. Interestingly, the residues that are
implicated in metal binding, H3A, H17A, and H21A, did not significantly change the amount of lipid
peroxidation in the presence of Cu2+, again reinforcing the importance of these residues to the activity of
gad-1.
The toxicity of the peptides against human erythrocytes was also analyzed to determine whether
gad-1 may be utilized as a potential therapeutic agent. Previous reports have shown that gad-1 is not
hemolytic towards cod erythrocytes but are partially hemolytic to human erythrocytes.28,113 Gad-1 and
mutants were shown to be ~100% hemolytic at 4 μM. The hemolytic activity of gad-1 reported here
differed from previous data, likely due to the method of data collection. Unfortunately, the hemolytic
activity overlapped with the MIC of gad-1 making it unlikely as a therapeutic agent for humans, however,
the potential for using gad-1 as an antimicrobial agent at fish farms is still an avenue of research to
consider. Previously, transgenic plants or fish that express AMPs have been created and gad-1 may be
utilized in fish farms to prevent disease.115,116
2.8 Conclusions
Gad-1, an AMP from the piscidin family, showed potent activity against E. coli and fish
pathogens, demonstrating its importance in the natural defense of G. morhua. The mechanism of action of
gad-1 was determined to be pore formation coupled with lipid peroxidation. The conservation of H
residues in the piscidin family occurs at H3, H4, H11, and H17, which are all present in the sequence of
gad-1 in addition to H21. The role of each H residue in the activity of gad-1 and the metal binding ability
was investigated here. It was shown that H3 is exceedingly important to the activity of gad-1 due to the
inclusion of this residue in the ATCUN motif. The presence of the ATCUN motif was shown to
potentiate activity by increasing the ROS formation and thereby increasing the lipid peroxidation and
potency of gad-1. Although it was found that H17 and H21 bind Zn2+ with low affinity, they are also
important residues for Cu2+ as it is postulated that they are involved in a second Cu2+ binding site. H17
may be crucial to the activity in nature as the activity was abolished when tested against fish pathogens.
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H4 did not seem to contribute to the antimicrobial activity of gad-1 with E. coli and only slightly with the
fish pathogens. Due to the high sequence conservation of the H in the piscidin family, it is probable that
the role may be similar to other piscidins. Therefore, H4 in gad-1 may be similar to TP4 in that H4 may
be important for antifungal activity rather than antibacterial activity.87 H11 and H21 were of interest
because both residues reside outside of the helical region.113 Unfortunately, a full set of data for H11A
was not collected, due to lack of available peptide. It was shown to be somewhat important but without
more data no meaningful conclusions about this substitution can be made at this time. H21 was shown to
have some impact on the MIC of gad-1 and may be important in binding to Cu2+. There was no
observable change in lipid peroxidation in the presence of Cu2+ for either H17A or H21A, indicating that
ROS may also be produced at the second binding site.
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CHAPTER 3
Experimental methods
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*Any water used was obtained from a Barnstead NANOpure Diamond filtration system with a 0.2 mm
pore size filter. Peptides were purchased from Atlantic peptides. All chemicals are from Sigma Aldrich
unless otherwise specified.
3.1 Cu2+ titration
A 1 mL solution of 1 mM peptide was diluted in 75 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES) and 100 mM NaCl (JT Baker) pH 7.40 buffer. Twenty mM
CuSO4 (JT Baker) stock in H2O was used and the peptide solution was titrated at intervals of 0.2
equivalents of Cu2+ until 3 equivalents was reached. After Cu2+ addition, the solution was mixed and
equilibrated for two minutes before each scan. The absorbance of the sample was read from 300-800 nm
using a Cary 50 Scan UV-Visible spectrophotometer (Varian). The titration was also repeated in water.
3.2 Zincon titration
A ZnSO4 solution was prepared in H2O at a concentration of 10 mM. A 1 mL solution of peptide
at 20 µM was added to 1 mL equimolar zincon (Alfa Aesar). The peptide was diluted using 75 mM
HEPES with 100 mM NaCl at a pH of 7.40. A 1 µL aliquot of 2 mM Zn2+ was added and the solution was
mixed and left to equilibrate for two minutes. The absorbance was then read from 300-800 nm. In total 4
equivalents of Zn2+ was added to the cuvette.
3.3 Electrospray ionization mass spectrometry (ESI-MS)
A 10 mM Cu2+ stock was prepared with CuSO4 in H2O. Twenty µL of 50 μM peptide was mixed
with Cu2+ in different ratios (1X, 2X, 3X, and 5X) in H2O and incubated for 45-60 minutes. Zn2+ was
similarly tested with 5X Zn2+ from Zn(C2H3O2)2 and 5 mM NH4C2H3O2 buffer was used instead of H2O.
Zn2+ was added to the peptide and the sample was also incubated for 45-60 minutes before injection. The
samples were run on a 4000-Q TRAP LC/MS/MS system by Applied Biosystems.
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3.4 CD measurements
The peptides were diluted to 50 µM in 300 µL of H2O or a 50:50 H2O:TFE mixture. They were
run on the Applied Photophysics ℼ*-18C instrument in a 0.1-cm quartz cuvette at room temperature. Each
sample was run with two replicates at 1.0 nm intervals from 250-190 nm. The bandwidth was 3 mm. Data
were analyzed using equation 1 to calculate the mean residue ellipticity (MRE, degree*cm2/dmol) where l
is pathlength in cm, c is concentration in M, and n is the number of residues.121 When metal ions were
added to the peptide samples, they were incubated for 45 to 60 minutes before analysis. The
concentrations of the peptides were determined immediately before making the dilutions to ensure that a
50 μM concentration was used. Percent helicity was calculated from equation 2.122

Equation 1. [θ]=

θ

10lcn

Equation 2. % helicity=−100 ∗

𝜃222 𝑛𝑚 +3000
33000

3.5 MIC and MBC measurements
All MIC assays utilized sterile 96-well polypropylene round bottom plates (Grenier). A 105 µL
aliquot of the peptide, at 256 µM, was prepared in Mueller Hinton Broth (MHB) media. In column one of
the plate, 100 µL of the peptide solution was plated. Then a 2-fold serial dilution was done until column
10. A sterility control contained 100 µL of MHB and a positive control consisted of 50 µL MHB and a 50
µL aliquot of bacteria. A 10 mL MHB culture was inoculated with two to five colonies of E. coli
MG1655 and incubated at 37˚C for four hours (midlog phase OD600~0.4). A 50 µL aliquot of the
inoculum was added to all wells except the sterility control, making the final concentration of cells 5X105.
Plates were examined after 18-20 hours. The MIC was determined based on visual turbidity, with the
MIC being the lowest concentration where growth did not occur. The minimal bactericidal concentration
(MBC) was subsequently determined by plating 10 µL of inoculum to a Luria Broth (LB) plate at MIC
concentration and 2X the MIC concentration. The plate was incubated for 18-20 hours at 37˚C and colony
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growth was observed. MIC and MBC values are reported as the mean and the data is representative of at
least three trials. The MIC in the presence of triethylenetetramine (TETA) was run with 400 μM TETA
that was added to the media to ensure that there was no labile Cu2+ ions. When testing Vibrio harveyi and
Aeromonas hydrophila LB with 2% and 1% NaCl, respectively, as these are optimal growth conditions
for these pathogens. The plates were grown for three days at room temperature and MBC plates were also
grown for three days at room temperature.
3.6 Time kill kinetics (TKK) measurements
Two to five E. coli MG1655 colonies were inoculated in a 10 mL MHB culture and incubated at
37˚C for four hours. The bacteria were diluted in MHB media to 1X106 cells. Peptide solutions at a
concentration of 8 µM were prepared in MHB media in a volume of 350 µL. The peptide solutions were
added to 350 µL of diluted E. coli in a 5 mL plastic tube. The positive control consisted of 350 µL of
MHB inoculated with 350 µL of E. coli. The samples were incubated at 37˚C with shaking at 234 rpm.
At each time point the samples were diluted appropriately (up to 10,000 fold) into MHB and 100 µL was
plated and spread on LB plates immediately after adding the bacteria at zero-hour and then at one-hour,
two-hour, and four-hour time points. The plates were incubated for 18-20 hours at 37˚C and the colonies
were counted to quantify the inhibition of growth. The data presented is representative of three trials.
3.7 β-galactosidase leakage assay
E. coli, transformed with the plasmid pUC19, was grown to an OD600 of 0.4 to 0.6. The cells were
induced by 1 mM isopropyl β-D-1thiogalactopyranoside (IPTG) for one hour and then washed with 5 mL
of phosphate buffered saline (PBS) 3X for ten minutes. The cells were resuspended to a culture volume of
10 mL of MHB. A 75 µL aliquot of bacteria was then incubated with 75 µL of peptide, diluted in PBS, at
a final concentration of 2 µM. The samples were incubated at 37˚C for one hour. The tubes were
centrifuged for ten minutes at 4˚C. A 100 µL aliquot of supernatant was added to 50 µL of 8 mg/mL onitrophenyl-β-D-galactopyranoside (ONPG, freshly prepared) in PBS. The 150 µL was then plated in a
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96-well plate and read every five minutes for one hour at 405 nm. The data is represented as a percentage
where 0.1% Triton X-100 is 100%. The negative control was PBS mixed with ONPG and this was
subtracted from all values before calculating the percentages. Data from the one-hour time point was used
and a total of three to four trials were done to confirm the activity.
3.8 Lipid peroxidation assay
MWF1, fabR::kan recD::Tn10, an E. coli strain with a high number of unsaturations in the
bilayer, was grown for four hours and was washed 3X with 20 mM HEPES and 100 mM NaCl buffer at
pH 7.4. The cells were resuspended in 10 mL of buffer and diluted to 2X107 cells. Peptide solutions were
prepared in buffer at 2X the final concentration (4 µM). An aliquot of 50 µL of diluted bacteria and 50 µL
of peptide solution were added and incubated for two hours at 37˚C. Once the treatment concluded, 100
µL of trichloroacetic acid (1% w/v) was added to each sample, followed by 800 µL of colorimetric
reagent (106 mg thiobarbatuic acid, 10 mL of 0.7 M NaOH, and 10 mL of 20% acetic acid). The samples
were vortexed and then added to a dry heat block at 97˚C for 60 minutes. The samples were put in a -20˚C
freezer for 10-20 minutes to cool to room temperature. The samples were centrifuged for ten minutes at
4˚C and then a 200 µL aliquot was added to a 96-well black plate in duplicate. The fluorescence was
recorded at 530 nm excitation and 550 nm emission and relative fluorescence intensity is reported.
Standards (0-5 µM) were run using 1,1,3,3-tetramethoxypropane, diluted in buffer. The data is
representative of four to five trials.
3.9 Hemolysis assay
A 150 µL solution of 16 µM peptide was prepared and serially diluted into PBS for a
concentration range of 8 to 0.5 µM. In a 15 mL sterile falcon tube, 1 mL of human erythrocytes were
added to 9 mL of PBS. This mixture was centrifuged for ten minutes at 4˚C and the supernatant was
removed until the supernatant was light pink. From the washed erythrocytes a 0.8% (v/v) solution in PBS
was prepared. A 75 µL aliquot of the diluted erythrocytes was added to 75 µL of serially diluted peptide
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and was incubated for one hour at 37˚C. The tubes were then centrifuged for five minutes and 100 µL of
supernatant was added to a 96-well polypropylene plate. This was read on a standard plate reader at 414
nm. PBS was used as a negative control and 1% Triton X-100 was used as the positive control. The
controls were run in duplicate for each of the three trials. Equation 3 was used to calculate the percent
hemolysis.

Equation 3. % ℎ𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 =

APeptide −APBS
ATriton−APBS

∗ 100%
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